These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36610815)

  • 21. Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment.
    Tachibana H; Inakawa T; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Anticancer Res; 2022 Jun; 42(6):3151-3158. PubMed ID: 35641290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma.
    Esterberg E; Iyer S; Nagar SP; Davis KL; Tannir NM
    Clin Genitourin Cancer; 2024 Apr; 22(2):115-125.e3. PubMed ID: 37914609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
    Waalkes S; Roos FC; Eggers H; Schumacher S; Janssen M; Wegener G; Thüroff JW; Hofmann R; Schrader M; Kuczyk MA; Schrader AJ;
    Urologe A; 2011 Sep; 50(9):1125-9. PubMed ID: 21845424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and long-term prognosis of papillary renal cell carcinoma.
    Schrader AJ; Rauer-Bruening S; Olbert PJ; Hegele A; Rustemeier J; Timmesfeld N; Varga Z; Hofmann R
    J Cancer Res Clin Oncol; 2009 Jun; 135(6):799-805. PubMed ID: 19023595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of Histological Variants on Oncological Outcomes After Surgical Resection of a Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus: A Multi-institutional Study.
    Fleury R; Bertail T; Bensalah K; Bernhard JC; Audenet F; Waeckel T; Parier B; Champy C; Olivier J; Doumerc N; Tricard T; Branger N; Bruyere F; Neuville P; Surlemont L; Alexandre Long J; Fontenil A; Vallee M; Roupret M; Boissier R; Jacques Patard J; Durand M; Ouzaid I; Rouget B; Durand X; Joncour C; Belas O; Denise Gomez F; Bigot P; Khene ZE;
    Eur Urol Open Sci; 2024 Apr; 62():123-130. PubMed ID: 38496822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus.
    Tilki D; Nguyen HG; Dall'Era MA; Bertini R; Carballido JA; Chromecki T; Ciancio G; Daneshmand S; Gontero P; Gonzalez J; Haferkamp A; Hohenfellner M; Huang WC; Koppie TM; Lorentz CA; Mandel P; Martinez-Salamanca JI; Master VA; Matloob R; McKiernan JM; Mlynarczyk CM; Montorsi F; Novara G; Pahernik S; Palou J; Pruthi RS; Ramaswamy K; Rodriguez Faba O; Russo P; Shariat SF; Spahn M; Terrone C; Vergho D; Wallen EM; Xylinas E; Zigeuner R; Libertino JA; Evans CP
    Eur Urol; 2014 Sep; 66(3):577-83. PubMed ID: 23871402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
    Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
    BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival.
    Pieretti AC; Shapiro DD; Westerman ME; Hwang H; Wang X; Segarra LA; Campbell MT; Tannir NM; Jonasch E; Matin SF; Wood CG; Karam JA
    Urol Oncol; 2021 Dec; 39(12):837.e9-837.e17. PubMed ID: 34551888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
    Kim SH; Lee DE; Joung JY; Seo HK; Lee KH; Chung J
    Investig Clin Urol; 2020 Mar; 61(2):146-157. PubMed ID: 32158965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.
    Meagher MF; Minervini A; Mir MC; Cerrato C; Rebez G; Autorino R; Hampton L; Campi R; Kriegmair M; Linares E; Hevia V; Musquera M; D'Anna M; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Marchioni M; Paksoy N; Erdem S; Derweesh IH
    Eur Urol Open Sci; 2024 May; 63():71-80. PubMed ID: 38572300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Chakiryan NH; Gore LR; Reich RR; Dunn RL; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain RK; Chahoud J; Spiess PE; Manley BJ; Sexton WJ; Hollenbeck BK; Gilbert SM
    JAMA Netw Open; 2022 May; 5(5):e2212347. PubMed ID: 35576003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer.
    Holland L; Bhanvadia R; Ibeziako N; Taylor J; Gerlt D; Chaplin I; Bagrodia A; Desai N; Gaston K; Lotan Y; Margulis V; Zhang T; Cole S; Woldu S
    Urol Oncol; 2024 Nov; 42(11):374.e11-374.e20. PubMed ID: 39034222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
    Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
    Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.
    Sheng IY; Gupta S; Reddy CA; Angelini D; Funchain P; Sussman TA; Sleiman J; Ornstein MC; McCrae K; Khorana AA
    Target Oncol; 2021 Nov; 16(6):813-821. PubMed ID: 34741719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.